NEW YORK--(BUSINESS WIRE)--
The Board of Directors of Bristol-Myers
Squibb Company (NYSE:BMY) today declared an increase of
approximately three percent in the company’s quarterly dividend,
beginning in the first quarter of 2016.
The dividend increase will result in a quarterly dividend of
thirty-eight cents ($0.38) per share on the $.10 par value Common Stock
of the corporation. The next quarterly dividend will be payable on
February 1, 2016, to stockholders of record at the close of business on
January 4, 2016.
The directors also declared a quarterly dividend of fifty cents ($0.50)
per share on the $2.00 Convertible Preferred Stock of the corporation,
payable March 1, 2016 to stockholders of record at the close of business
on February 5, 2016.
The directors indicated an expected dividend for the full year of 2016
of $1.52 per share on the $.10 par value Common Stock of the
corporation, subject to the normal quarterly review by the Board.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Forward-looking Statement
This press release contains "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual outcomes and
results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Among other risks, there
can be no guarantee that the Board will approve a quarterly dividend in
future quarters or that the dividend for the full year of 2015 will be
the amount indicated in this press release. Forward-looking statements
in this press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business, particularly
those identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2014, in our Quarterly Reports on Form 10-Q and our Current Reports on
Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151208006563/en/
Source: Bristol-Myers Squibb